Cediranib: Difference between revisions

Latest revision as of 03:31, 13 February 2025

Cediranib[edit]

Cediranib is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors, primarily used in the treatment of certain types of cancer. It is an oral medication that targets the VEGF receptor tyrosine kinases, which play a crucial role in angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting these receptors, Cediranib can reduce the blood supply to tumors, thereby inhibiting their growth.

Mechanism of Action[edit]

Cediranib works by selectively inhibiting the activity of VEGF receptors 1, 2, and 3. These receptors are critical for the signaling pathways that promote angiogenesis. By blocking these pathways, Cediranib effectively reduces the proliferation and migration of endothelial cells, which are essential for new blood vessel formation. This action starves tumors of the necessary nutrients and oxygen supplied by the blood, leading to reduced tumor growth and potential tumor shrinkage.

Clinical Uses[edit]

Cediranib has been investigated for use in various types of cancer, including ovarian cancer, colorectal cancer, and non-small cell lung cancer. It is often studied in combination with other chemotherapeutic agents to enhance its efficacy. Clinical trials have shown that Cediranib can improve progression-free survival in patients with certain cancers, although its use is associated with some adverse effects.

Side Effects[edit]

The use of Cediranib can lead to several side effects, which are common with VEGF inhibitors. These include hypertension, fatigue, diarrhea, and hand-foot syndrome. More serious side effects can include thromboembolic events, gastrointestinal perforations, and hemorrhage. Patients receiving Cediranib require careful monitoring for these potential adverse effects.

Research and Development[edit]

Cediranib is still under investigation in various clinical trials to better understand its efficacy and safety profile. Researchers are exploring its use in combination with other targeted therapies and immunotherapies to enhance its anti-tumor effects. Ongoing studies aim to identify biomarkers that can predict which patients are most likely to benefit from Cediranib treatment.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Cediranib''' is an oral [[small molecule inhibitor]] of [[VEGF receptors]] 1, 2, and 3, which are implicated in the pathogenesis of [[cancer]] by promoting [[angiogenesis]] - the formation of new blood vessels. By inhibiting these receptors, cediranib reduces the blood supply to tumors, thereby inhibiting their growth and spread. It is primarily investigated for its potential in treating various types of cancer, including [[ovarian cancer]], [[colorectal cancer]], and [[glioblastoma]].
+== Cediranib ==
-==Mechanism of Action==
+[[File:Cediranib.svg|thumb|right|Chemical structure of Cediranib]]
-Cediranib acts by targeting and inhibiting the activity of VEGF receptors 1, 2, and 3. These receptors, upon binding with their ligand VEGF (Vascular Endothelial Growth Factor), initiate a signaling cascade that promotes endothelial cell proliferation, migration, and survival. These processes are crucial for angiogenesis. By inhibiting these receptors, cediranib impedes the angiogenic process, thereby starving tumors of the necessary blood supply needed for their growth and survival.
-==Clinical Trials==
+'''Cediranib''' is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors, primarily used in the treatment of certain types of cancer. It is an oral medication that targets the VEGF receptor tyrosine kinases, which play a crucial role in angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting these receptors, Cediranib can reduce the blood supply to tumors, thereby inhibiting their growth.
-Cediranib has been evaluated in several [[clinical trial]]s for its efficacy and safety in treating various cancers. In ovarian cancer, it has been studied as a single agent and in combination with other chemotherapeutic agents. Studies have shown that cediranib, when combined with standard chemotherapy, may improve progression-free survival in patients with recurrent ovarian cancer.
-In glioblastoma, cediranib has been explored due to its ability to cross the [[blood-brain barrier]], making it a potential treatment option for brain tumors. Clinical trials have investigated its use both as a monotherapy and in combination with other treatments, such as [[radiotherapy]] and [[temozolomide]].
+== Mechanism of Action ==
-For colorectal cancer, research has focused on cediranib's role in combination therapy, assessing its effectiveness in conjunction with other targeted therapies and chemotherapeutic agents.
+Cediranib works by selectively inhibiting the activity of [[VEGF receptor|VEGF receptors]] 1, 2, and 3. These receptors are critical for the signaling pathways that promote angiogenesis. By blocking these pathways, Cediranib effectively reduces the proliferation and migration of endothelial cells, which are essential for new blood vessel formation. This action starves tumors of the necessary nutrients and oxygen supplied by the blood, leading to reduced tumor growth and potential tumor shrinkage.
-==Adverse Effects==
+== Clinical Uses ==
-The inhibition of VEGF signaling by cediranib can lead to several adverse effects, reflecting its mechanism of action on vascular function. Common side effects include [[hypertension]], [[fatigue]], [[diarrhea]], and [[hand-foot syndrome]]. More severe but less common side effects may include gastrointestinal perforation, hemorrhage, and reversible posterior leukoencephalopathy syndrome (RPLS).
-==Current Status==
+Cediranib has been investigated for use in various types of cancer, including [[ovarian cancer]], [[colorectal cancer]], and [[non-small cell lung cancer]]. It is often studied in combination with other chemotherapeutic agents to enhance its efficacy. Clinical trials have shown that Cediranib can improve progression-free survival in patients with certain cancers, although its use is associated with some adverse effects.
-As of the last update, cediranib is not yet approved by major regulatory bodies like the [[U.S. Food and Drug Administration]] (FDA) for any indication. However, it remains under investigation in clinical trials for its potential use in various cancer types. Its development and clinical trial results are closely watched by the medical and scientific community for its promising role in cancer therapy.
-==See Also==
+== Side Effects ==
-* [[Angiogenesis inhibitors]]
-* [[Cancer therapy]]
-* [[VEGF]]
-* [[Clinical trial]]
-[[Category:Cancer treatment]]
+The use of Cediranib can lead to several side effects, which are common with VEGF inhibitors. These include hypertension, fatigue, diarrhea, and hand-foot syndrome. More serious side effects can include thromboembolic events, gastrointestinal perforations, and hemorrhage. Patients receiving Cediranib require careful monitoring for these potential adverse effects.
-[[Category:Experimental drugs]]
-[[Category:Angiogenesis inhibitors]]
-{{Medicine-stub}}
+== Research and Development ==
+Cediranib is still under investigation in various clinical trials to better understand its efficacy and safety profile. Researchers are exploring its use in combination with other targeted therapies and immunotherapies to enhance its anti-tumor effects. Ongoing studies aim to identify biomarkers that can predict which patients are most likely to benefit from Cediranib treatment.
+== Related Pages ==
+* [[Angiogenesis]]
+* [[VEGF receptor]]
+* [[Cancer treatment]]
+* [[Tyrosine kinase inhibitor]]
+[[Category:Antineoplastic drugs]]
+[[Category:Tyrosine kinase inhibitors]]